Literature DB >> 25582538

Novel oral anticoagulants: what dermatologists need to know.

Molly Plovanich1, Arash Mostaghimi2.   

Abstract

The development of novel oral anticoagulants provides clinicians and patients a welcome alternative to the challenges of warfarin therapy. Dermatologists must be aware of the potential impact of novel oral anticoagulants on their surgical and medical practice. This review provides a concise summary of the novel oral anticoagulants for dermatologists with particular emphasis on: (1) the pharmacokinetic properties of these drugs and how they differ from warfarin, (2) suggested management during cutaneous surgery, (3) adverse drug interactions with commonly prescribed medications in dermatology, and (4) potential use within dermatology for treatment of disorders of cutaneous thrombosis.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anticoagulation; apixaban; cutaneous surgery; dabigatran; novel drugs; rivaroxaban; warfarin

Mesh:

Substances:

Year:  2015        PMID: 25582538     DOI: 10.1016/j.jaad.2014.11.013

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  1 in total

Review 1.  [Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants].

Authors:  C Löser; A Nast; U Zeymer
Journal:  Hautarzt       Date:  2019-11       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.